Novel Treatment Strategies to Improve Outcomes in Patients with Relapsing Remitting Multiple Sclerosis


Program Dates: April 10th, 2020 - April 9th, 2021
Credits: 1.0 AMA PRA Category 1 Credit™


Novel Treatment Strategies to Improve Outcomes in Patients with Relapsing Remitting Multiple Sclerosis

Program Overview

This CME program, derived from content presented at the Advanced Curriculum for Multiple Sclerosis 2020 Course in West Palm Beach, Florida, will highlight novel treatment strategies to improve outcomes in patients with relapsing remitting multiple sclerosis (RRMS). The expert faculty will review the science of relapsing remitting multiple sclerosis, including risk mitigation and the pharmacokinetics of current therapeutic options. Safety, efficacy and tolerability data for novel therapeutic options for the treatment of RRMS will also be discussed. The faculty will review how to utilize individualized treatment strategies to effectively reduce the rate of multiple sclerosis relapses and slow the progression of disability in MS patients.

Target Audience

Neurologists and other healthcare professionals who care for patients with MS

Agenda

I. Relapsing Remitting Multiple Sclerosis: The Importance of Risk Mitigation & the Pharmacokinetics of Novel Therapeutic Options

II. The Safety, Efficacy, and Tolerability Data for Novel Therapeutic Options for the Treatment of RRMS

III. Utilize individualized treatment strategies to more effectively reduce the rate of MS relapses and slow the progression of disability

Learning Objectives

  1. Understand the science of relapsing remitting multiple sclerosis, including risk mitigation and the pharmacokinetics of novel therapeutic options
  2. Review the safety, efficacy, and tolerability data for novel therapeutic options for the treatment of RRMS
  3. Utilize individualized treatment strategies to more effectively reduce the rate of MS relapses and slow the progression of disability

Faculty

 

Fred D. Lublin, MD
Saunders Family Professor of Neurology
Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
New York, New York

 

Mark S. Freedman, MSc, MD
Professor of Medicine (Neurology)
University of Ottawa
Sr. Scientist
The Ottawa Hospital Research Institute
Ottawa, Ontario, Canada

 

Stephen Krieger, MD
Associate Professor of Neurology
Icahn School of Medicine at Mount Sinai
Attending Neurologist
Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai Medical Center
New York, New York

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:

Fred D. Lublin, MD

 

Consultant/Advisor: Actelion Pharmaceuticals; Apitope; Atara Biotherapeutics; Biogen; Brainstorm Cell Therapeutics; EMD Serono, Inc.; GW Pharmaceuticals; Innate Immunotherapeutics; Jazz Pharmaceuticals; MedDay Pharmaceuticals; Mapi Pharma; MedImmune, LLC/Viela Bio; Novartis Pharmaceuticals Corporation; Orion Biotechnology; Polpharma Group; Population Council; Receptos, Inc./Celgene Corporation; Roche Group/Genentech Inc.; Sanofi Genzyme; Teva Pharmaceuticals; TG Therapeutics, Inc.
Grant/Research Support: Novartis International AG; Actelion Pharmaceuticals; Biogen Inc.; Sanofi U.S.; NMSS; NIH; Brainstorm Cell Therapeutics
Speaker’s Bureau: Sanofi U.S.

Mark S. Freedman, MSc, MD

Consultant/Advisor: Actelion Pharmaceuticals; Alexion Pharmaceuticals; Atara Biotherapeutics; Bayer Healthcare; Biogen; Clene Nanomedicine, Inc.; EMD Serono, Inc.; EMD Serono, Inc. (Canada); Hoffman La-Roche; Janssen; MedDay Pharmaceuticals

Grant/Research Support: EMD Serono, Inc.; Sanofi-Genzyme Canada Pharmaceuticals; Novartis Pharmaceuticals; Sanofi Genzyme; Celgene Corporation (BMS); Chugai; Teva Canada Innovation

Speaker’s Bureau: EMD Serono, Inc.; Sanofi-Genzyme

Stephen Krieger, MD

Consultant/Advisor: Biogen; EMD Serono; Genentech Inc.; Genzyme; Mallinckrodt Pharmaceuticals; MedDay Pharmaceuticals; Novartis International AG; Teva Pharmaceutical Industries Ltd.; TG Therapeutics
Speakers Bureau: Biogen Inc.; EMD Serono, Inc.; Genentech Inc.; Novartis International AG

Planners and Peer Reviewers

Timothy Hayes, MD, PhD; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Screen Shot 2018-12-11 at 12.19.42 PM

Credit Designation Statements

AcademicCME designates this live material for a maximum of 1.0 AMA PRA Category 1 CreditTM.

Financial Support

This activity has been supported by an independent educational grant from Biogen

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Biogen do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions andcomplete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact [email protected].

BUTTON

 

Provided by: AcademicCME-web